SOPHiA GENETICS (SOPH) Liabilities and Shareholders Equity (2020 - 2025)

SOPHiA GENETICS has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $163.0 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $163.0 million, up 4.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $650.8 million (down 6.26% YoY), and the FY2025 annual result was $163.0 million, up 4.97% from the prior year.
• Liabilities and Shareholders Equity came in at $163.0 million for Q4 2025 at SOPHiA GENETICS, roughly flat from $163.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $334.9 million in Q3 2021 to a low of $104.0 million in Q2 2021.
• The 5-year median for Liabilities and Shareholders Equity is $205.9 million (2023), against an average of $212.7 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 166.45% in 2022, while the deepest fall reached 25.18% in 2022.
• SOPHiA GENETICS's Liabilities and Shareholders Equity stood at $320.2 million in 2021, then declined by 23.84% to $243.8 million in 2022, then slipped by 15.45% to $206.2 million in 2023, then retreated by 24.66% to $155.3 million in 2024, then gained by 4.97% to $163.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $163.0 million (Q4 2025), $163.5 million (Q3 2025), and $177.6 million (Q2 2025), per Business Quant data.